The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...

Novo Nordisk blueprints $1.2B rare disease production ... While Novo has at long last won regulatory recognition for concizumab in the U.S., the path to approval has been anything but easy.

With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

recommending the approval of Alhemo (concizumab) for haemophilia A or B with inhibitors. A final decision is expected soon. Alhemo is not approved in the United States. Novo Nordisk is trading ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...

Denmark-based pharma giant Novo Nordisk has announced plans to invest ... The company’s haemophilia portfolio includes Alhemo (concizumab) and its antibody asset Mim8, with the Phase III ...